Champions Oncology (CSBR) Q2 2026 earnings review
Top-Line Recovery Masked by OpEx Explosion
Champions Oncology delivered a visually strong quarter on the surface: Revenue grew 11.5% to $15.0M and Oncology Services margins expanded significantly to 52%. However, the bottom line deteriorated. Adjusted EBITDA fell 26% YoY to $843k, and Net Income dropped 67%. The culprit is a deliberate, massive spike in operating expenses—specifically R&D (+55%) and G&A (+57%)—aimed at scaling the data platform. Management is effectively spending all gross profit gains (and then some) on future growth initiatives, turning a 'harvest' quarter into an 'investment' quarter.
🐂 Bull Case
Oncology Services margin hit 52%, up significantly from 45% a year ago and 43% last quarter. The company actually reduced Cost of Sales by 2.2% while growing revenue 11.5%, demonstrating genuine leverage in the core lab business.
After a dip in late FY25, revenue has accelerated sequentially ($14.0M to $15.0M) and YoY (+11.5%). Bookings quality has improved, and the company is seeing higher conversion rates.
🐻 Bear Case
Despite positive Net Income, Operating Cash Flow was negative ($1.9M) due to a bloat in Accounts Receivable. Cash on hand dropped to $8.5M from $9.8M six months ago. With rising OpEx, the liquidity cushion is thinning.
The company grew revenue by $1.5M YoY, but increased Operating Expenses by $2.1M. R&D and G&A are growing 5x faster than revenue. If the Data Platform doesn't monetize quickly, this cost structure is unsustainable.
⚖️ Verdict: ⚪
Neutral. The core business is healthy (excellent margins, growing sales), but the financial profile has shifted riskily towards high-spend 'growth mode.' Investors are funding a Data Platform bet that is currently consuming cash rather than generating it.
Key Themes
Gross Margin Efficiency
Accelerating. The standout metric this quarter was the Oncology Services margin hitting 52%, a massive jump from the ~45% range seen in recent history. This was driven by a decrease in outsourced lab costs and operational efficiencies. If CSBR can maintain >50% margins while growing revenue, the core business is highly profitable before corporate overhead.
Aggressive OpEx Expansion
Accelerating (Negatively). R&D expense surged 55% YoY to $2.6M, and G&A jumped 57% to $3.0M. Management cites 'targeted investments' in the data platform and IT infrastructure. While strategic, this spending velocity completely erased the leverage gained from the gross margin expansion.
Working Capital Deterioration
Reversing. Cash flow from operations swung to a usage of $1.9M, primarily driven by an increase in Accounts Receivable. While revenue grew 11.5%, the inability to collect cash efficiently in the quarter put pressure on the balance sheet, reducing cash reserves to $8.5M.
Data Platform Transition
Stable/Ongoing. Management continues to pivot the narrative toward the Data Platform as a long-term value creator. While they claim it will 'contribute meaningfully,' it currently introduces volatility and cost. The transition from a pure-play service lab to a tech-enabled data company is in the expensive 'build' phase.
Macro Environment Stabilization
Stable. CEO Robert Brainin noted 'cautious optimism' regarding pharma/biotech funding. The bookings quality improvement suggests that while the sector isn't booming, the freeze seen in FY24 has thawed enough to support low-double-digit growth.
Other KPIs
Accelerating. Up 11.5% YoY and 7.1% sequentially. This marks a return to double-digit growth after a volatile FY25.
Decelerating. Down significantly from $728,000 in the prior year period. While positive, the margin is razor-thin due to the heavy OpEx load.
Decelerating. Down from $1.1M YoY. EBITDA margin compressed to 5.6% from 8.4% a year ago, despite the gross margin expansion.
Guidance
Stable. Reaffirmed expectation for growth. Given H1 FY26 revenue is $29.0M vs $27.6M H1 FY25 (+5.4%), and considering the 11.5% growth in Q2, the company implies continued momentum in H2.
Stable. Reaffirmed target for positive Adj. EBITDA for the full year. With H1 Adj. EBITDA at $962k, the company has some buffer but must manage the rising OpEx carefully to avoid dipping into the red in H2.
Key Questions
OpEx Ceiling
R&D and G&A expenses grew over 50% this quarter. Is $5.6M in combined quarterly R&D/G&A the new run rate, or were there one-time startup costs for the data platform included in Q2?
Accounts Receivable Spike
Operating cash flow was negative $1.9M largely due to receivables. Is this a collection issue with specific large clients, or a change in payment terms to secure the data contracts mentioned?
Data Revenue Contribution
You mentioned the data business introduces variability. Can you quantify the contribution of Data License revenue in Q2 vs Q1, and is the margin profile of these specific revenues meeting the 'high margin' expectation?
Gross Margin Sustainability
Services margin hit 52% due to 'efficiencies.' Are these structural changes (permanent cost outs) or volume-dependent? Can we model 50%+ margins for H2?